References
- Liénard D, Ewalenko P, Delmotte JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:50–62.
- Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose TNF, gamma-IFN and melphalan. Cancer 1994;73:482–92.
- Eggermont AM, Liénard D, Schraffordt Koop H, et al. High dose tumor necrosis factor-alpha in isolation perfusion of the limb: highly effective treatment for melanoma in transit metastases or unresectable sarcoma. Reg Cancer Treat 1995;7:32–36.
- Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479–89.
- Liénard D, Eggermont AM, Schraffordt Koops H, et al.: Isolated limb perfusion with tumor necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999;9:491–502.
- Hill S, Fawcett WJ, Sheldon J, et al. Low dose tumor necrosis factor-alpha and melphalan in hyperthermic isolated limb perfusion. Br J Surg 1993;80:995–97.
- Di Filippo F, Rossi CR, Garinei R, et al. Hyperthermic Antiblastic Perfusion with TFNα and Melphalan in stage III limb melanoma patients: A Phase I-II SITILO Study. J Exp Clin Cancer Res 2003; 22(4):97–101.
- Rossi CR, Foletto M, Mocellin S, Pilati PL, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-[alpha] and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004;11(2):173–77.
- Brouckaert PGG, Leroux-Rouls GG, Guisez Y, Tavernier J, Fiers W. In vivo anti-tumor activity of recombinant human and murine TNF, alone and in combination with IFN-gamma on a syngeneic murine melanoma. Int J Cancer 1996; 38:763–69.
- Steinmann G. An open, randomized prospective trial to compare the efficacy and safety of TNFalpha 1a and melphalan with melphalan alone via isolated limb perfusion for metastatic melanoma of the limb. In: Christine Clark, ed. Beromun, Second Expert Meeting. Barcelona 2001:16–18.
- Fraker D, Alexander H, Ross M, et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis factor (TNF) plus interferon gamma (IFN). Ann Surg Oncol 2002; 9:S8.
- Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncology 2003; 4(7): 429–437.
- de Wilt JH, ten Hagen TL, de Boech G, von Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer 2000;82:1000–3.
- de Wilt JH, Manusama ER, von Tiel ST et al. Prerequisites for effective isolated limb perfusion using Tumor Necrosis Factor Alpha and melphalan in rats. BR J Cancer 1999;8:161–6.
- Rosenblum MG, Donato NJ, Gutterman JU. Characterization of human recombinant tumor necrosis factoralpha antiproliferative effects on human cells in culture. Lymphokine Res 1988;7:107–17.